Clinical trials: Respiratory Physiological Phenomena
Asthma
Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of single doses of three different dry powder inhalation formulations of AZD3199 administered via Single Inhalation Device (SID) compared to…
- Trial name
- NCT01348139
- Testing
- AZD3199
- Where
- 3 sites in Sweden
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
COPD, COPD Exacerbation
A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination
Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination is commonly prescribed to treat COPD; we will perform a retrospective analysis on the effect of adding a long-acting muscarinic receptor antagonist (LAMA) to…
- Trial name
- RETRIEVE (NCT03858348)
- Where
- Greece
- Volunteers
- 1,000 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Pulmonary Disease, Chronic Obstructive
A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary purpose of this study is to assess the equivalence of closed triple therapy Fluticasone Furoate (FF)/Umeclidinium (UMEC)/Vilanterol (VI) to open triple therapy (FF/VI + UMEC), with a comparison of both triple…
- Trial name
- NCT02731846
- Testing
- Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg, Fluticasone furoate 100 mcg + Vilanterol 25 mcg, Umeclidinium 62.5 mcg
- Where
- 11 sites in Canada, Germany
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak…
- Trial name
- NCT03095456
- Testing
- Revefenacin, Spiriva Handihaler®
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Mylan Inc.
Asthma
Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients
The number of people with of asthma and allergy is still increasing and a large number of patients still do not have their asthma well controlled.
- Trial name
- NCT02427165
- Testing
- RPL554, Salbutamol
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 29 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
COPD (Chronic Obstructive Pulmonary Disease)
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD
The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in…
- Trial name
- NCT06075095
- Testing
- BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg
- Where
- 87 sites in United States, Argentina and 12 more
- Volunteers
- 297 people
- Sponsor
- AstraZeneca
Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00640315
- Testing
- Riociguat (Adempas, BAY63-2521) 1.0 mg, Riociguat (Adempas, BAY63-2521) 2.5 mg
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
COPD
Comparing Pressure Based and Dilution Based Total Lung Capacity Measurements in COPD Patients for Lung Function Diagnostics
Total Lung Capacity (TLC) of the lungs can be determined using a pressure based method (i.e. by body plethysmography) or it can be determined using a dilution based method (i.e.
- Trial name
- NCT04531293
- Testing
- Respiratory Analysis System
- Where
- Switzerland
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- ndd Medizintechnik AG
Pulmonary Disease, Chronic Obstructive
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC, administered once daily by the RESPIMAT Inhaler after 6 weeks of treatment.
- Trial name
- NCT01559116
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
- Trial name
- NCT00363896
- Testing
- Aclidinium bromide
- Where
- 132 sites in Andorra, Austria and 14 more
- Volunteers
- 843 people
- Sponsor
- AstraZeneca
Cystic Fibrosis
A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)
This study is open to adult men with cystic fibrosis and adult women with cystic fibrosis who cannot have children. People with cystic fibrosis can join if they are not eligible to receive cystic fibrosis transmembrane…
- Trial name
- NCT06515002
- Testing
- BI 3720931, Inhaler
- Where
- 5 sites in France, Italy and 3 more
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
This study is a multiple within participant crossover study to evaluate the effect of ivacaftor on lung function in participants aged 12 years and older with cystic fibrosis (CF) who have phenotypic or molecular evidence of…
- Trial name
- NCT01685801
- Testing
- Ivacaftor
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Idiopathic Pulmonary Fibrosis
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. People taking standard medicines for IPF, including antifibrotic medicines, can continue taking them throughout the study.
- Trial name
- NCT04419506
- Testing
- BI 1015550
- Where
- 75 sites in United States, Argentina and 20 more
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
Asthma
Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects
This study is designed to look at the safety aspects and effects of repeat inhaled doses of GW597901X in asthmatics to develop this drug for its use in asthma and Chronic Obstructive Pulmonary Disease(COPD).
- Trial name
- NCT00354042
- Testing
- GW597901X
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care
This is a prospective, observational, non-drug interventional, non-randomized study to compare the rate of moderate-severe COPD exacerbations in patients of all Chronic Obstructive Pulmonary Disease (COPD) severities with and…
- Trial name
- ACCESS (NCT01516528)
- Testing
- Spirometry
- Where
- 233 sites in Belgium, France and 4 more
- Volunteers
- 3,500 people
- Sponsor
- GlaxoSmithKline
Asthma in Children
Safety and Feasibility of a Novel Device for Assessing Respiratory Function in Children
This is an early phase pilot study designed to test the safety and feasibility of using a novel, wireless, wearable device (Leo) for assessing respiratory parameters (lung volume, respiration rate, heart rate and indices related…
- Trial name
- NCT04873193
- Testing
- Leo device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- ResMed
Haemorrhage
A Non-investigational Product (IP) Study to Investigate Lung Function in Women in the Third Stage of Labour
The purpose of this study is to record and compare the inhalation profiles of non pregnant women and those who are in the third stage of labour.
- Trial name
- NCT02106000
- Testing
- Inhalation profile recorder
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD
Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol
The purpose of this study is to assess the change in inspiratory capacity and lung function in patients with chronic obstructive pulmonary disease when treated with indacaterol compared to placebo and formoterol.
- Trial name
- NCT00422552
- Testing
- Indacaterol (QAB149)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Novartis
Emphysema, COPD
Distribution of Regional Lung Function by Vibration Response Imaging
Assessment of regional contribution of different areas of the lung to its integrated function is often required, such as prior to lung resection in the presence of tumor or emphysema.
- Trial name
- NCT01229020
- Testing
- Observational study - no intervention
- Where
- Israel
- Volunteers
- 25 people
- Sponsor
- Deep Breeze
Chronic Obstructive Pulmonary Disease, COPD
Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients
The study is a multicenter, randomized, 2-period, open-label, two arm, cross-over study to show the superior effect of a 4 week treatment each with QVA149 versus tiotropium on lung function.
- Trial name
- FAVOR (NCT02125734)
- Testing
- QVA149, Tiotropium
- Where
- 18 sites in Germany
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals